Casado MA, Buti M, Gómez MR, Monterde J, Esteban R
La realización de un tratamiento individualizado (´a la carta´) por paciente con hepatitis crónica C genera un ahorro de costes en el hospital
51 Congreso Nacional de la Sociedad Española de Farmacia Hospitalaria (SEFH). Málaga, España. 27-29 sep 2006
Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, Esteban R
The improved therapeutic effects of adefovir dipivoxil in patients with HBe-Ag-negative chronic hepatitis B offset against its increased cost compared to lamivudine
41st Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria. 26-30 apr 2006
Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, Esteban R
Coste-efectividad e impacto presupuestario del tratamiento a 4 años con adefovir dipivoxil o lamivudina en pacientes HBeAg negativos con hepatitis crónica B
XXXI Congreso Nacional de la Asociación Española para el Estudio del Hígado (AEEH). Madrid, España. 15-17 feb 2006
Casado MA
Coste-efectividad de interferón pegilado alfa en el tratamiento de la hepatitis crónica por virus C
Gastroenterol Hepatol. 2006;29(Supl. 2):200-5
Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, Esteban R
A Cost-effectiveness analysis of two oral antiviral drugs for treatment of HBeAg-negative chronic hepatitis B patient
Aliment Pharmacol Ther. 2006;23:409-19
Buti M, Wong J, Casado MA, Esteban R
Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients
J Hepatol. 2006;44(Suppl 1):S60-S64
Wong JB, Buti M, Casado MA, Fosbrook L, Soriano V, Esteban R
Cost-effectiveness of peginterferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-HCV co-infected patients
56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and awarded a Presidential Poster of Distinction. San Francisco, California, EEUU. 11-15 nov 2005
Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, Esteban R
Long-term treatment with adefovir dipivoxil is more cost-effective than lamivudine for HBeAg-negative patients with chronic hepatitis B
56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, California, EEUU. 11-15 nov 2005
Wong JB, Buti M, Casado MA, Fosbrook L, Soriano V, Esteban R